{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["HIV-1 integrase", "design and synthesis", "indole-2-carboxylic acid", "structural optimization", "virtual screening"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "38138510", "DateCompleted": {"Year": "2023", "Month": "12", "Day": "25"}, "DateRevised": {"Year": "2023", "Month": "12", "Day": "25"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "12", "Day": "08"}], "Language": ["eng"], "ELocationID": ["8020", "10.3390/molecules28248020"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "28", "Issue": "24", "PubDate": {"Year": "2023", "Month": "Dec", "Day": "08"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "The Discovery of Indole-2-carboxylic Acid Derivatives as Novel HIV-1 Integrase Strand Transfer Inhibitors.", "Abstract": {"AbstractText": ["As an important antiviral target, HIV-1 integrase plays a key role in the viral life cycle, and five integrase strand transfer inhibitors (INSTIs) have been approved for the treatment of HIV-1 infections so far. However, similar to other clinically used antiviral drugs, resistance-causing mutations have appeared, which have impaired the efficacy of INSTIs. In the current study, to identify novel integrase inhibitors, a set of molecular docking-based virtual screenings were performed, and indole-2-carboxylic acid was developed as a potent INSTI scaffold. Indole-2-carboxylic acid derivative <b>3</b> was proved to effectively inhibit the strand transfer of HIV-1 integrase, and binding conformation analysis showed that the indole core and C2 carboxyl group obviously chelated the two Mg<sup>2+</sup> ions within the active site of integrase. Further structural optimizations on compound <b>3</b> provided the derivative <b>20a</b>, which markedly increased the integrase inhibitory effect, with an IC<sub>50</sub> value of 0.13 \u03bcM. Binding mode analysis revealed that the introduction of a long branch on C3 of the indole core improved the interaction with the hydrophobic cavity near the active site of integrase, indicating that indole-2-carboxylic acid is a promising scaffold for the development of integrase inhibitors."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang 550004, China."}, {"Identifier": [], "Affiliation": "Center for Tissue Engineering and Stem Cell Research, Key Laboratory of Regenerative Medicine of Guizhou Province, School of Basic Medical Sciences, Guizhou Medical University, Guiyang 550004, China."}, {"Identifier": [], "Affiliation": "School of Pharmacy, Guizhou Medical University, Guian New District, Guiyang 550025, China."}], "LastName": "Wang", "ForeName": "Yu-Chan", "Initials": "YC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang 550004, China."}, {"Identifier": [], "Affiliation": "School of Pharmacy, Guizhou Medical University, Guian New District, Guiyang 550025, China."}], "LastName": "Zhang", "ForeName": "Wen-Li", "Initials": "WL"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang 550004, China."}, {"Identifier": [], "Affiliation": "Center for Tissue Engineering and Stem Cell Research, Key Laboratory of Regenerative Medicine of Guizhou Province, School of Basic Medical Sciences, Guizhou Medical University, Guiyang 550004, China."}], "LastName": "Zhang", "ForeName": "Rong-Hong", "Initials": "RH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang 550004, China."}], "LastName": "Liu", "ForeName": "Chun-Hua", "Initials": "CH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmacy, Guizhou Medical University, Guian New District, Guiyang 550025, China."}], "LastName": "Zhao", "ForeName": "Yong-Long", "Initials": "YL"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmacy, Xinxiang University, Xinxiang 453000, China."}], "LastName": "Yan", "ForeName": "Guo-Yi", "Initials": "GY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmacy, Guizhou Medical University, Guian New District, Guiyang 550025, China."}], "LastName": "Liao", "ForeName": "Shang-Gao", "Initials": "SG"}, {"Identifier": ["0000-0002-0479-6259"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang 550004, China."}], "LastName": "Li", "ForeName": "Yong-Jun", "Initials": "YJ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang 550004, China."}, {"Identifier": [], "Affiliation": "School of Pharmacy, Guizhou Medical University, Guian New District, Guiyang 550025, China."}], "LastName": "Zhou", "ForeName": "Meng", "Initials": "M"}], "GrantList": [{"GrantID": "qiankehejichu [2020]1Z008, qiankehejichu-ZK[2021]yiban551, qiankehezhicheng [2021]yiban425, YQK[2023]031", "Agency": "Guizhou Institute of Technology", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "YY6481J2FF", "NameOfSubstance": "p31 integrase protein, Human immunodeficiency virus 1"}, {"RegistryNumber": "0", "NameOfSubstance": "HIV Integrase Inhibitors"}, {"RegistryNumber": "1477-50-5", "NameOfSubstance": "indole-2-carboxylic acid"}, {"RegistryNumber": "EC 2.7.7.-", "NameOfSubstance": "HIV Integrase"}, {"RegistryNumber": "0", "NameOfSubstance": "Indoles"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["pharmacology", "chemistry"], "DescriptorName": "HIV Integrase Inhibitors"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "HIV-1"}, {"QualifierName": ["metabolism"], "DescriptorName": "HIV Integrase"}, {"QualifierName": ["drug therapy"], "DescriptorName": "HIV Infections"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Indoles"}, {"QualifierName": [], "DescriptorName": "Catalytic Domain"}, {"QualifierName": [], "DescriptorName": "Drug Resistance, Viral"}, {"QualifierName": [], "DescriptorName": "Mutation"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Yoshimura K. Current status of HIV/AIDS in the ART era. J. Infect. Chemother. 2017;23:12\u201316. doi: 10.1016/j.jiac.2016.10.002.", "ArticleIdList": ["10.1016/j.jiac.2016.10.002", "27825722"]}, {"Citation": "Pomerantz R.J., Horn D.L. Twenty years of therapy for HIV-1 infection. Nat. Med. 2003;9:867\u2013873. doi: 10.1038/nm0703-867.", "ArticleIdList": ["10.1038/nm0703-867", "12835707"]}, {"Citation": "Amariles P., Rivera-Cadavid M., Ceballos M. Clinical relevance of drug interactions in people living with human immunodeficiency virus on antiretroviral therapy-update 2022: Systematic review. Pharmaceutics. 2023;15:2488. doi: 10.3390/pharmaceutics15102488.", "ArticleIdList": ["10.3390/pharmaceutics15102488", "PMC10610003", "37896248"]}, {"Citation": "Lesbats P., Engelman A.N., Cherepanov P. Retroviral DNA integration. Chem. Rev. 2016;116:12730\u201312757. doi: 10.1021/acs.chemrev.6b00125.", "ArticleIdList": ["10.1021/acs.chemrev.6b00125", "PMC5084067", "27198982"]}, {"Citation": "Eid A., Qi Y. Prime editor integrase systems boost targeted DNA insertion and beyond. Trends Biotechnol. 2022;40:907\u2013909. doi: 10.1016/j.tibtech.2022.05.002.", "ArticleIdList": ["10.1016/j.tibtech.2022.05.002", "35667925"]}, {"Citation": "Ruelas D.S., Greene W.C. An integrated overview of HIV-1 latency. Cell. 2013;155:519\u2013529. doi: 10.1016/j.cell.2013.09.044.", "ArticleIdList": ["10.1016/j.cell.2013.09.044", "PMC4361081", "24243012"]}, {"Citation": "Hazuda D.J. HIV integrase as a target for antiretroviral therapy. Curr. Opin. HIV AIDS. 2012;7:383\u2013389. doi: 10.1097/COH.0b013e3283567309.", "ArticleIdList": ["10.1097/COH.0b013e3283567309", "22871634"]}, {"Citation": "Chiu K.T., Davies R.D. Structure and function of HIV-1 integrase. Curr. Top. Med. Chem. 2004;4:965\u2013977. doi: 10.2174/1568026043388547.", "ArticleIdList": ["10.2174/1568026043388547", "15134551"]}, {"Citation": "Gill M.S.A., Hassan S.S., Ahemad N. Evolution of HIV-1 reverse transcriptase and integrase dual inhibitors: Recent advances and developments. Eur. J. Med. Chem. 2019;179:423\u2013448. doi: 10.1016/j.ejmech.2019.06.058.", "ArticleIdList": ["10.1016/j.ejmech.2019.06.058", "31265935"]}, {"Citation": "Zhao X.Z., Smith S.J., Maskell D.P., M\u00e9tifiot M., Pye V.E., Fesen K., Marchand C., Pommier Y., Cherepanov P., Hughes S.H., et al. Structure-guided optimization of HIV integrase strand transfer inhibitors. J. Med. Chem. 2017;60:7315\u20137332. doi: 10.1021/acs.jmedchem.7b00596.", "ArticleIdList": ["10.1021/acs.jmedchem.7b00596", "PMC5601359", "28737946"]}, {"Citation": "Aknin C., Smith E.A., Marchand C., Andreola M.-L., Pommier Y., Metifiot M. Discovery of novel integrase inhibitors acting outside the active site through high-throughput screening. Molecules. 2019;24:3675. doi: 10.3390/molecules24203675.", "ArticleIdList": ["10.3390/molecules24203675", "PMC6832134", "31614773"]}, {"Citation": "Ramkumar K., Yarovenko V.N., Nikitina A.S., Zavarzin I.V., Krayushkin M.M., Kovalenko L.V., Esqueda A., Odde S., Neamati N. Design, Synthesis and structure-activity studies of rhodanine derivatives as HIV-1 integrase inhibitors. Molecules. 2010;15:3958\u20133992. doi: 10.3390/molecules15063958.", "ArticleIdList": ["10.3390/molecules15063958", "PMC6264390", "20657419"]}, {"Citation": "Wang Y., Gu S.-X., He Q., Fan R. Advances in the development of HIV integrase strand transfer inhibitors. Eur. J. Med. Chem. 2021;225:113787. doi: 10.1016/j.ejmech.2021.113787.", "ArticleIdList": ["10.1016/j.ejmech.2021.113787", "34425310"]}, {"Citation": "Mahajan P.S., Smith S.J., Hughes S.H., Zhao X., Burke T.R. A practical approach to bicyclic carbamoyl pyridones with application to the synthesis of HIV-1 integrase strand transfer inhibitors. Molecules. 2023;28:1428. doi: 10.3390/molecules28031428.", "ArticleIdList": ["10.3390/molecules28031428", "PMC9919513", "36771093"]}, {"Citation": "Rashamuse T.J., Fish M.Q., Coyanis E.M., Bode M.L. Studies towards the design and synthesis of novel 1,5-diaryl-1H-imidazole-4-carboxylic acids and 1,5-diaryl-1H-imidazole-4-carbohydrazides as host LEDGF/p75 and HIV-1 integrase interaction inhibitors. Molecules. 2021;26:6203. doi: 10.3390/molecules26206203.", "ArticleIdList": ["10.3390/molecules26206203", "PMC8540437", "34684786"]}, {"Citation": "Summa V., Petrocchi A., Bonelli F., Crescenzi B., Donghi M., Ferrara M., Fiore F., Gardelli C., Gonzalez Paz O., Hazuda D.J., et al. Discovery of Raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J. Med. Chem. 2008;51:5843\u20135855. doi: 10.1021/jm800245z.", "ArticleIdList": ["10.1021/jm800245z", "18763751"]}, {"Citation": "Shimura K., Kodama E.N. Elvitegravir: A new HIV integrase inhibitor. Antivir. Chem. Chemother. 2009;20:79\u201385. doi: 10.3851/IMP1397.", "ArticleIdList": ["10.3851/IMP1397", "19843978"]}, {"Citation": "Dow D.E., Bartlett J.A. Dolutegravir, the second-generation of integrase strand transfer inhibitors (INSTIs) for the treatment of HIV. Infect. Dis. Ther. 2014;3:83\u2013102. doi: 10.1007/s40121-014-0029-7.", "ArticleIdList": ["10.1007/s40121-014-0029-7", "PMC4269626", "25134686"]}, {"Citation": "Rowan-Nash A.D., Korry B.J., Mylonakis E., Belenky P. Cross-domain and viral interactions in the microbiome. Microbiol. Mol. Biol. Rev. 2019;83:10\u20131128. doi: 10.1128/MMBR.00044-18.", "ArticleIdList": ["10.1128/MMBR.00044-18", "PMC6383444", "30626617"]}, {"Citation": "Swindells S., Andrade-Villanueva J.-F., Richmond G.J., Rizzardini G., Baumgarten A., Masi\u00e1 M., Latiff G., Pokrovsky V., Bredeek F., Smith G., et al. Long-acting Cabotegravir and Rilpivirine for maintenance of HIV-1 suppression. N. Engl. J. Med. 2020;382:1112\u20131123. doi: 10.1056/NEJMoa1904398.", "ArticleIdList": ["10.1056/NEJMoa1904398", "32130809"]}, {"Citation": "M\u00e9tifiot M., Johnson B.C., Kiselev E., Marler L., Zhao X.Z., Burke T.R., Jr., Marchand C., Hughes S.H., Pommier Y. Selectivity for strand-transfer over 3\u2032-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme\u2013DNA interactions in the active site. Nucleic Acids Res. 2016;44:6896\u20136906. doi: 10.1093/nar/gkw592.", "ArticleIdList": ["10.1093/nar/gkw592", "PMC5001616", "27369381"]}, {"Citation": "Hare S., Maertens G.N., Cherepanov P. 3\u2032-Processing and strand transfer catalysed by retroviral integrase in crystallo. EMBO J. 2012;31:3020\u20133028. doi: 10.1038/emboj.2012.118.", "ArticleIdList": ["10.1038/emboj.2012.118", "PMC3395085", "22580823"]}, {"Citation": "Wainberg M.A., Zaharatos G.J., Brenner B.G. Development of antiretroviral drug resistance. N. Engl. J. Med. 2011;365:637\u2013646. doi: 10.1056/NEJMra1004180.", "ArticleIdList": ["10.1056/NEJMra1004180", "21848464"]}, {"Citation": "Tao K., Rhee S.-Y., Chu C., Avalos A., Ahluwalia A.K., Gupta R.K., Jordan M.R., Shafer R.W. Treatment emergent Dolutegravir resistance mutations in individuals na\u00efve to HIV-1 integrase inhibitors: A rapid scoping review. Viruses. 2023;15:1932. doi: 10.3390/v15091932.", "ArticleIdList": ["10.3390/v15091932", "PMC10536831", "37766338"]}, {"Citation": "Hurt C.B., Sebastian J., Hicks C.B., Eron J.J. Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009\u20132012. Clin. Infect. Dis. 2014;58:423\u2013431. doi: 10.1093/cid/cit697.", "ArticleIdList": ["10.1093/cid/cit697", "PMC3890334", "24145878"]}, {"Citation": "Smith S.J., Zhao X.Z., Burke T.R., Hughes S.H. Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants. Retrovirology. 2018;15:37. doi: 10.1186/s12977-018-0420-7.", "ArticleIdList": ["10.1186/s12977-018-0420-7", "PMC5956922", "29769116"]}, {"Citation": "Cook N.J., Li W., Berta D., Badaoui M., Ballandras-Colas A., Nans A., Kotecha A., Rosta E., Engelman A.N., Cherepanov P. Structural basis of second-generation HIV integrase inhibitor action and viral resistance. Science. 2020;367:806\u2013810. doi: 10.1126/science.aay4919.", "ArticleIdList": ["10.1126/science.aay4919", "PMC7023979", "32001525"]}, {"Citation": "Passos D.O., Li M., J\u00f3\u017awik I.K., Zhao X.Z., Santos-Martins D., Yang R., Smith S.J., Jeon Y., Forli S., Hughes S.H., et al. Structural basis for strand-transfer inhibitor binding to HIV intasomes. Science. 2020;367:810\u2013814. doi: 10.1126/science.aay8015.", "ArticleIdList": ["10.1126/science.aay8015", "PMC7357238", "32001521"]}, {"Citation": "Zhang C., Xie Q., Wan C.C., Jin Z., Hu C. Recent advances in small-molecule HIV-1 integrase inhibitors. Curr. Med. Chem. 2021;28:4910\u20134934. doi: 10.2174/0929867328666210114124744.", "ArticleIdList": ["10.2174/0929867328666210114124744", "33459224"]}, {"Citation": "Diller D.J., Merz K.M., Jr. High throughput docking for library design and library prioritization. Proteins. 2001;43:113\u2013124. doi: 10.1002/1097-0134(20010501)43:2<113::AID-PROT1023>3.0.CO;2-T.", "ArticleIdList": ["10.1002/1097-0134(20010501)43:2<113::AID-PROT1023>3.0.CO;2-T", "11276081"]}, {"Citation": "Rao S.N., Head M.S., Kulkarni A., LaLonde J.M. Validation studies of the site-directed docking program LibDock. J. Chem. Inf. Model. 2007;47:2159\u20132171. doi: 10.1021/ci6004299.", "ArticleIdList": ["10.1021/ci6004299", "17985863"]}, {"Citation": "Wu J., Ma Y., Zhou H., Zhou L., Du S., Sun Y., Li W., Dong W., Wang R. Identification of protein tyrosine phosphatase 1B (PTP1B) inhibitors through De Novo Evoluton, synthesis, biological evaluation and molecular dynamics simulation. Biochem. Biophys. Res. Commun. 2020;526:273\u2013280. doi: 10.1016/j.bbrc.2020.03.075.", "ArticleIdList": ["10.1016/j.bbrc.2020.03.075", "32209254"]}, {"Citation": "Chang T.T., Sun M.F., Chen H.Y., Tsai F.J., Fisher M., Lin J.G., Chen C.Y. Screening from the world\u2019s largest TCM database against H1N1 virus. J. Biomol. Struct. Dyn. 2011;28:773\u2013786. doi: 10.1080/07391102.2011.10508605.", "ArticleIdList": ["10.1080/07391102.2011.10508605", "21294588"]}, {"Citation": "Wang S., Jiang J.H., Li R.Y., Deng P. Docking-based virtual screening of T\u03b2R1 inhibitors: Evaluation of pose prediction and scoring functions. BMC Chem. 2020;14:52. doi: 10.1186/s13065-020-00704-3.", "ArticleIdList": ["10.1186/s13065-020-00704-3", "PMC7427878", "32818203"]}, {"Citation": "Xue X., Zhang Y., Liu Z., Song M., Xing Y., Xiang Q., Wang Z., Tu Z., Zhou Y., Ding K., et al. Discovery of benzo[cd]indol-2(1H)-ones as potent and specific BET bromodomain inhibitors: Structure-based virtual screening, optimization, and biological evaluation. J. Med. Chem. 2016;59:1565\u20131579. doi: 10.1021/acs.jmedchem.5b01511.", "ArticleIdList": ["10.1021/acs.jmedchem.5b01511", "26731490"]}, {"Citation": "Jiang Z., You Q., Zhang X. Medicinal chemistry of metal chelating fragments in metalloenzyme active sites: A perspective. Eur. J. Med. Chem. 2019;165:172\u2013197. doi: 10.1016/j.ejmech.2019.01.018.", "ArticleIdList": ["10.1016/j.ejmech.2019.01.018", "30684796"]}, {"Citation": "Mbhele N., Chimukangara B., Gordon M. HIV-1 integrase strand transfer inhibitors: A review of current drugs, recent advances and drug resistance. Int. J. Antimicrob. Agents. 2021;57:106343. doi: 10.1016/j.ijantimicag.2021.106343.", "ArticleIdList": ["10.1016/j.ijantimicag.2021.106343", "33852932"]}, {"Citation": "Kapewangolo P., Tawha T., Nawinda T., Knott M., Hans R. Sceletium tortuosum demonstrates in vitro anti-HIV and free radical scavenging activity. S. Afr. J. Bot. 2016;106:140\u2013143. doi: 10.1016/j.sajb.2016.06.009.", "ArticleIdList": ["10.1016/j.sajb.2016.06.009"]}, {"Citation": "Jiang F., Chen W., Yi K., Wu Z., Si Y., Han W., Zhao Y. The evaluation of catechins that contain a galloyl moiety as potential HIV-1 integrase inhibitors. Clin. Immunol. 2010;137:347\u2013356. doi: 10.1016/j.clim.2010.08.007.", "ArticleIdList": ["10.1016/j.clim.2010.08.007", "20832370"]}, {"Citation": "Ivashchenko A.A., Ivanenkov Y.A., Koryakova A.G., Karapetian R.N., Mitkin O.D., Aladinskiy V.A., Kravchenko D.V., Savchuk N.P., Ivashchenko A.V. Synthesis, biological evaluation and in silico modeling of novel integrase strand transfer inhibitors (INSTIs) Eur. J. Med. Chem. 2020;189:112064. doi: 10.1016/j.ejmech.2020.112064.", "ArticleIdList": ["10.1016/j.ejmech.2020.112064", "31972393"]}, {"Citation": "Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001;46:3\u201326. doi: 10.1016/S0169-409X(00)00129-0.", "ArticleIdList": ["10.1016/S0169-409X(00)00129-0", "11259830"]}, {"Citation": "Baell J.B., Holloway G.A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. 2010;53:2719\u20132740. doi: 10.1021/jm901137j.", "ArticleIdList": ["10.1021/jm901137j", "20131845"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "11", "Day": "7"}, {"Year": "2023", "Month": "11", "Day": "26"}, {"Year": "2023", "Month": "11", "Day": "29"}, {"Year": "2023", "Month": "12", "Day": "25", "Hour": "6", "Minute": "42"}, {"Year": "2023", "Month": "12", "Day": "23", "Hour": "12", "Minute": "43"}, {"Year": "2023", "Month": "12", "Day": "23", "Hour": "1", "Minute": "16"}, {"Year": "2023", "Month": "12", "Day": "8"}], "PublicationStatus": "epublish", "ArticleIdList": ["38138510", "PMC10745497", "10.3390/molecules28248020", "molecules28248020"]}}], "PubmedBookArticle": []}